Berberine reduces circulating inflammatory mediators in patients with severe COVID-19

Br J Surg. 2021 Jan 27;108(1):e9-e11. doi: 10.1093/bjs/znaa021.

Authors

B Y Zhang¹, M Chen¹, X C Chen¹, K Cao¹, Y You¹, Y J Qian¹, W K Yu¹

Affiliation

¹ Department of Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, Jiangsu Province 210008, China.

No abstract available

MeSH terms

Anti-Inflammatory Agents / therapeutic use*
Antiviral Agents / therapeutic use*
Berberine / therapeutic use*
COVID-19 / blood*
COVID-19 Drug Treatment*
Cytokine Release Syndrome / blood
Cytokine Release Syndrome / drug therapy
Humans
Inflammation Mediators / blood*
Prospective Studies
SARS-CoV-2

Substances

Anti-Inflammatory Agents
Antiviral Agents
Inflammation Mediators
Berberine